Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Public ClinicalTrials.gov record NCT05446870. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with standard of care (SOC) therapy than in those receiving pembrolizumab + SOC therapy.
Study identification
- NCT ID
- NCT05446870
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 160 participants
Conditions and interventions
Interventions
- Pembrolizumab Biological
- Paclitaxel Drug
- Carboplatin Drug
- Avastin Biological
- MK-4830 Biological
- Docetaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 25, 2022 (Actual)
- Primary completion
- Dec 20, 2023 (Actual)
- Completion
- Oct 16, 2024 (Actual)
- Last update posted
- Oct 1, 2025
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus-Cancer Clinical Trials Office ( Site 0108) | Aurora | Colorado | 80045 | — |
| Mayo Clinic in Florida ( Site 0101) | Jacksonville | Florida | 32224 | — |
| Miami Cancer Institute at Baptist Health, Inc. ( Site 0110) | Miami | Florida | 33176 | — |
| Northwestern Memorial Hospital ( Site 0104) | Chicago | Illinois | 60611 | — |
| Washington University ( Site 0113) | St Louis | Missouri | 63110 | — |
| Rutgers Cancer Institute of New Jersey ( Site 0114) | New Brunswick | New Jersey | 08901 | — |
| Roswell Park Cancer Institute ( Site 0106) | Buffalo | New York | 14263 | — |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0116) | Mineola | New York | 11501 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0107) | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0102) | New York | New York | 10065 | — |
| Sanford Cancer Center-Gynecologic Oncology ( Site 0115) | Sioux Falls | South Dakota | 57104 | — |
| Fred Hutchinson Cancer Center ( Site 0100) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05446870, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05446870 live on ClinicalTrials.gov.